全球首个！脑机接口技术获重要突破

Core Insights - The article highlights a significant breakthrough in clinical brain-machine interface technology, specifically for precise tumor boundary localization during surgery, marking the first global clinical trial of its kind [1][2]. Group 1: Technology Development - The clinical trial was conducted by the Aerospace Information Research Institute and the First Affiliated Hospital of Harbin Medical University, utilizing the NeuroDepth microelectrode developed by the Aerospace Institute [1]. - The technology includes a high-throughput neural signal detection device (AIRCAS-128) that synchronously collects and analyzes vast amounts of neural signals, converting raw signals into precise "lesion navigation" data for real-time tumor boundary assessment [1]. Group 2: Clinical Application - This technology overcomes the limitations of traditional neural electrodes, which could only detect signals from the brain's surface and shallow layers, allowing for detection across all brain regions, including deep brain areas [2]. - It can also simultaneously detect chemical signals such as dopamine and glutamate, providing comprehensive data to differentiate between tumor and normal tissue, which is crucial for accurate surgical planning and execution [2].